ANDA 78509, held by Strides Pharma. Efavirenz.
As of Nov 16, 2026, ANDA 78509 (Efavirenz), held by Strides Pharma, was first approved by FDA on Jun 16, 2021, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 16, 2021 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Efavirenz600MG · tablet;oral | Efavirenz | Discontinued |
| Dec 2, 2024 | Supplement 25Labeling · Standard review | Approved | None posted |
| Jun 16, 2021 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters